![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PRDX2 |
Gene summary for PRDX2 |
![]() |
Gene information | Species | Human | Gene symbol | PRDX2 | Gene ID | 7001 |
Gene name | peroxiredoxin 2 | |
Gene Alias | HEL-S-2a | |
Cytomap | 19p13.13 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P32119 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7001 | PRDX2 | GSM4909281 | Human | Breast | IDC | 1.18e-02 | 3.08e-01 | 0.21 |
7001 | PRDX2 | GSM4909282 | Human | Breast | IDC | 6.87e-39 | 6.09e-01 | -0.0288 |
7001 | PRDX2 | GSM4909285 | Human | Breast | IDC | 4.48e-60 | 8.36e-01 | 0.21 |
7001 | PRDX2 | GSM4909286 | Human | Breast | IDC | 6.82e-03 | 1.06e-01 | 0.1081 |
7001 | PRDX2 | GSM4909287 | Human | Breast | IDC | 4.67e-12 | 3.41e-01 | 0.2057 |
7001 | PRDX2 | GSM4909289 | Human | Breast | IDC | 7.11e-06 | 4.58e-01 | 0.1064 |
7001 | PRDX2 | GSM4909290 | Human | Breast | IDC | 2.92e-18 | 5.08e-01 | 0.2096 |
7001 | PRDX2 | GSM4909291 | Human | Breast | IDC | 1.69e-03 | 2.53e-01 | 0.1753 |
7001 | PRDX2 | GSM4909293 | Human | Breast | IDC | 5.60e-14 | 4.91e-01 | 0.1581 |
7001 | PRDX2 | GSM4909294 | Human | Breast | IDC | 7.78e-26 | 4.87e-01 | 0.2022 |
7001 | PRDX2 | GSM4909296 | Human | Breast | IDC | 1.93e-27 | 3.68e-01 | 0.1524 |
7001 | PRDX2 | GSM4909297 | Human | Breast | IDC | 2.46e-22 | 1.06e-01 | 0.1517 |
7001 | PRDX2 | GSM4909301 | Human | Breast | IDC | 2.42e-04 | 2.52e-01 | 0.1577 |
7001 | PRDX2 | GSM4909302 | Human | Breast | IDC | 2.82e-07 | 2.14e-01 | 0.1545 |
7001 | PRDX2 | GSM4909304 | Human | Breast | IDC | 6.66e-42 | 7.09e-01 | 0.1636 |
7001 | PRDX2 | GSM4909305 | Human | Breast | IDC | 1.98e-02 | 1.96e-01 | 0.0436 |
7001 | PRDX2 | GSM4909306 | Human | Breast | IDC | 1.79e-20 | 5.49e-01 | 0.1564 |
7001 | PRDX2 | GSM4909307 | Human | Breast | IDC | 1.45e-15 | 4.35e-01 | 0.1569 |
7001 | PRDX2 | GSM4909308 | Human | Breast | IDC | 2.01e-34 | 6.23e-01 | 0.158 |
7001 | PRDX2 | GSM4909309 | Human | Breast | IDC | 4.81e-02 | 9.66e-02 | 0.0483 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00714511 | Oral cavity | NEOLP | cellular response to superoxide | 8/2005 | 25/18723 | 3.46e-03 | 2.05e-02 | 8 |
GO:003210212 | Oral cavity | NEOLP | negative regulation of response to external stimulus | 63/2005 | 420/18723 | 3.67e-03 | 2.14e-02 | 63 |
GO:004665122 | Oral cavity | NEOLP | lymphocyte proliferation | 46/2005 | 288/18723 | 3.72e-03 | 2.15e-02 | 46 |
GO:003294312 | Oral cavity | NEOLP | mononuclear cell proliferation | 46/2005 | 291/18723 | 4.54e-03 | 2.54e-02 | 46 |
GO:004341013 | Oral cavity | NEOLP | positive regulation of MAPK cascade | 70/2005 | 480/18723 | 4.59e-03 | 2.56e-02 | 70 |
GO:200123911 | Oral cavity | NEOLP | regulation of extrinsic apoptotic signaling pathway in absence of ligand | 11/2005 | 43/18723 | 4.65e-03 | 2.56e-02 | 11 |
GO:00427446 | Oral cavity | NEOLP | hydrogen peroxide catabolic process | 9/2005 | 32/18723 | 5.18e-03 | 2.78e-02 | 9 |
GO:002240822 | Oral cavity | NEOLP | negative regulation of cell-cell adhesion | 33/2005 | 196/18723 | 5.76e-03 | 3.04e-02 | 33 |
GO:00003032 | Oral cavity | NEOLP | response to superoxide | 8/2005 | 28/18723 | 7.44e-03 | 3.73e-02 | 8 |
GO:00003052 | Oral cavity | NEOLP | response to oxygen radical | 8/2005 | 29/18723 | 9.33e-03 | 4.43e-02 | 8 |
GO:200123318 | Prostate | BPH | regulation of apoptotic signaling pathway | 134/3107 | 356/18723 | 5.06e-22 | 7.84e-19 | 134 |
GO:000697918 | Prostate | BPH | response to oxidative stress | 142/3107 | 446/18723 | 8.11e-16 | 1.36e-13 | 142 |
GO:006219718 | Prostate | BPH | cellular response to chemical stress | 110/3107 | 337/18723 | 2.44e-13 | 2.40e-11 | 110 |
GO:200123418 | Prostate | BPH | negative regulation of apoptotic signaling pathway | 79/3107 | 224/18723 | 7.67e-12 | 5.94e-10 | 79 |
GO:009719118 | Prostate | BPH | extrinsic apoptotic signaling pathway | 77/3107 | 219/18723 | 1.67e-11 | 1.19e-09 | 77 |
GO:200123618 | Prostate | BPH | regulation of extrinsic apoptotic signaling pathway | 59/3107 | 151/18723 | 3.07e-11 | 2.02e-09 | 59 |
GO:004206018 | Prostate | BPH | wound healing | 123/3107 | 422/18723 | 5.74e-11 | 3.59e-09 | 123 |
GO:000030218 | Prostate | BPH | response to reactive oxygen species | 76/3107 | 222/18723 | 9.75e-11 | 5.92e-09 | 76 |
GO:003459918 | Prostate | BPH | cellular response to oxidative stress | 90/3107 | 288/18723 | 4.70e-10 | 2.43e-08 | 90 |
GO:004873218 | Prostate | BPH | gland development | 122/3107 | 436/18723 | 1.13e-09 | 5.01e-08 | 122 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRDX2 | SNV | Missense_Mutation | novel | c.544A>T | p.Thr182Ser | p.T182S | P32119 | protein_coding | deleterious(0.03) | possibly_damaging(0.515) | TCGA-A7-A4SA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
PRDX2 | SNV | Missense_Mutation | novel | c.565N>T | p.Asp189Tyr | p.D189Y | P32119 | protein_coding | deleterious(0.01) | benign(0.102) | TCGA-OL-A66L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRDX2 | insertion | Frame_Shift_Ins | novel | c.245_246insGGGAGGAGGTTGCAGTAAG | p.His83GlyfsTer30 | p.H83Gfs*30 | P32119 | protein_coding | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PRDX2 | SNV | Missense_Mutation | novel | c.169N>A | p.Ala57Thr | p.A57T | P32119 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRDX2 | SNV | Missense_Mutation | novel | c.452C>T | p.Ser151Phe | p.S151F | P32119 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRDX2 | SNV | Missense_Mutation | rs534702204 | c.334T>C | p.Ser112Pro | p.S112P | P32119 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
PRDX2 | SNV | Missense_Mutation | rs755166073 | c.448N>T | p.Arg150Cys | p.R150C | P32119 | protein_coding | deleterious(0.05) | probably_damaging(0.98) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PRDX2 | SNV | Missense_Mutation | rs764907738 | c.559N>A | p.Val187Met | p.V187M | P32119 | protein_coding | tolerated(0.06) | benign(0.376) | TCGA-CM-4746-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PRDX2 | SNV | Missense_Mutation | rs369634820 | c.272G>A | p.Arg91Gln | p.R91Q | P32119 | protein_coding | deleterious(0.03) | possibly_damaging(0.74) | TCGA-D5-7000-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PRDX2 | SNV | Missense_Mutation | c.38N>T | p.Pro13Leu | p.P13L | P32119 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |